BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Career Advice

  10 Resume Mistakes to Avoid at All Costs

  Crafting a well-organized, powerful resume is important to leave a great impact on recruiters. But all your hard work can go in vain if you make these resume mistakes.

  February 6, 2019

   · 

  3 min read

   · 

  Editorial Staff
• Business

  Jennewein Biotechnologie and Yili Group join forces in China for microbiome research and human milk oligosaccharides to bring innovation to the largest baby food market

  China represents the largest market for baby food globally

  February 6, 2019

   · 

  4 min read
• Business

  Suven Revenue up by 40.24%; PAT up by 40.27% for quarter ended December’ 2018

  Suven Life Sciences Limited announced its Un-audited financial results for the quarter ended 31st December 2018.

  February 6, 2019

   · 

  2 min read
• 

  Business

  Gladstone Institutes’ Robert Mahley Launches Alzheimer’s Biotech GABAeron

  Robert Mahley, founder and president of Gladstone Institutes, an internationally-recognized expert on heart disease, cholesterol metabolism and Alzheimer’s disease, is launching a biotech company to focus on Alzheimer’s disease. The company is called GABAeron.

  February 6, 2019

   · 

  3 min read

   · 

  Mark Terry
• Business

  GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message

  Applauding HIV Elimination Goals and Encouraging More Resources Toward Vaccine Development

  February 6, 2019

   · 

  4 min read
• 

  Business

  GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018

  Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017

  February 6, 2019

   · 

  5 min read
• Amprologix secures funding to develop new antibiotic with Ingenza

  Ingenza is pleased to announce that University of Plymouth spin-out Amprologix, in which it has a stake, has been awarded a £1.2 million contract from the UK Department of Health and Social Care to accelerate the development and scale up its lead antibiotic candidate, Epidermicin NI01.

  February 6, 2019

   · 

  2 min read
• 

  Business

  Merck KGaA Expands in Massachusetts Following $4 Billion Deal With GSK

  Merck KGaA, Darmstadt, Germany and GlaxoSmithKline forged an agreement to develop an immunotherapy for difficult to treat cancers that could be worth up to $4 billion. Following the announcement, a subsidiary of Merck KGaA announced plans to expand its Billerica, Mass. R&D facility.

  February 6, 2019

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  GSK Cuts Six Respiratory Assets as It Continues to Focus on Oncology Treatments

  GlaxoSmithKline has been in the midst of a significant reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company has made some cuts to its pipeline, including six quietly announced this morning in the company’s year-end report.

  February 6, 2019

   · 

  3 min read

   · 

  Alex Keown
• Business

  MorphoSys Announces Appointment of David Trexler as President and Member of the Board of Directors of MorphoSys US Inc.

  MorphoSys AG announced the appointment of David R. Trexler as President and member of the Board of Directors of MorphoSys US Inc., effective February 6, 2019.

  February 6, 2019

   · 

  5 min read